Suppr超能文献

组蛋白去乙酰化酶抑制剂通过上调Snail诱导上皮-间质转化促进癌症进展。

Histone deacetylase inhibitor induction of epithelial-mesenchymal transitions via up-regulation of Snail facilitates cancer progression.

作者信息

Jiang Guan-Min, Wang Hong-Sheng, Zhang Fan, Zhang Kun-Shui, Liu Zong-Cai, Fang Rui, Wang Hao, Cai Shao-Hui, Du Jun

机构信息

Department of Clinical Laboratory, The First Affiliated Hospital of University of South China, Hengyang, 421001, PR China.

出版信息

Biochim Biophys Acta. 2013 Mar;1833(3):663-71. doi: 10.1016/j.bbamcr.2012.12.002. Epub 2012 Dec 12.

Abstract

Histone deacetylase inhibitors (HDACIs) are now emerging as a new class of anticancer drugs. Some of them have been used in clinical treatment for tumors, most impressively in the hematological tumors. But their single-agent activities in epithelial-derived tumors are limited. The mechanisms of these actions of HDACIs are not yet well understood. In this study, it was found for the first time that HDACIs were able to induce epithelial-mesenchymal transitions (EMT) which is believed to trigger tumor cell invasion and metastasis. We show that HDACIs induce fibroblast-like morphology, up-regulate Snail and Vimentin and down-regulate E-cadherin in epithelial cell-derived tumor cell lines. It demonstrates that HDACI treatment enhances further Snail acetylation and reduces its ubiquitylation, and induces Snail transcription as well as Snail nuclear translocation in CNE2 cells. Snail knockdown by siRNAs prevents the change in cell morphology and Vimentin up-regulation in response to HDACIs. The results suggested that Snail plays an important role in the HDACI-induced EMT. It is very crucial for a better understanding of clinical therapeutical failure of HDACIs in the patients with epithelial cell-derived cancers. Therefore, our results indicate that more attention should be paid to the cancer treatment using HDACIs due to the fact that it will enhance the spread risks of cancer cells to facilitate cancer progression and it is very important to select appropriate drugs for different tumors.

摘要

组蛋白去乙酰化酶抑制剂(HDACIs)正作为一类新型抗癌药物崭露头角。其中一些已用于肿瘤的临床治疗,在血液系统肿瘤中表现最为突出。但它们在上皮来源肿瘤中的单药活性有限。HDACIs这些作用的机制尚未完全明确。在本研究中,首次发现HDACIs能够诱导上皮-间质转化(EMT),而EMT被认为会引发肿瘤细胞的侵袭和转移。我们发现HDACIs可使上皮细胞来源的肿瘤细胞系呈现成纤维细胞样形态,上调Snail和波形蛋白(Vimentin)并下调E-钙黏蛋白(E-cadherin)。结果表明,HDACI处理可增强CNE2细胞中Snail的乙酰化并减少其泛素化,诱导Snail转录以及Snail核转位。通过小干扰RNA(siRNAs)敲低Snail可防止细胞形态改变以及响应HDACIs时波形蛋白上调。这些结果提示Snail在HDACI诱导的EMT中起重要作用。这对于更好地理解HDACIs在上皮细胞来源癌症患者中的临床治疗失败至关重要。因此,我们的结果表明,鉴于HDACIs会增加癌细胞扩散风险以促进癌症进展,且针对不同肿瘤选择合适药物非常重要,所以在癌症治疗中应更多关注使用HDACIs的情况。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验